Head-to-head clinical analysis & difference comparison: details on mechanism of action, dosing, half-life, interactions, and maternal-fetal safety.
ALPHACAINE vs POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES
Clinician-reviewed, head-to-head comparison of mechanism, dosing, pharmacokinetics, and safety profiles.
Last clinically reviewed: July 2026 · OpiCalc Medical Review Team
ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.
Polyethylene glycol 3350 is an osmotic laxative that acts by retaining water in the stool, increasing stool volume, and stimulating colonic peristalsis. Electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate) are included to maintain fluid and electrolyte balance and prevent shifts.
Local anesthesia for dental procedures,Local anesthesia for minor surgical procedures,Epidural anesthesia (off-label),Peripheral nerve blocks (off-label)
Bowel cleansing prior to colonoscopy,Treatment of acute constipation in specific formulations
10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.
4 liters of PEG-3350 and electrolytes solution orally as a single dose for colonoscopy preparation; alternative split-dose regimen: 2 liters evening before and 2 liters morning of procedure. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water once daily, up to 3 days.
Terminal elimination half-life: 3.5-5.0 hours (prolonged in hepatic impairment; requires dose adjustment in Child-Pugh B or C).
Not applicable; PEG 3350 is not metabolized and is eliminated non-kinetically. Clinical effect occurs during colonic transit; residual drug cleared within 24–48 hours post-dose.
ALPHACAINE is metabolized primarily by the liver via cytochrome P450 enzymes, specifically CYP3A4 and CYP1A2, to inactive metabolites that are excreted renally.
Polyethylene glycol 3350 is not significantly metabolized; it is excreted unchanged in feces and urine. Electrolytes are absorbed and metabolized according to normal physiological pathways.
Renal: ~60-70% unchanged; Hepatic metabolism: ~20-30% via CYP3A4 and CYP2C9; Fecal: <10%.
Primarily fecal (unchanged); minimal renal excretion (<2%) as intact polymer. Electrolytes absorbed and renally excreted.
~92-95% bound, primarily to albumin and alpha-1-acid glycoprotein.
PEG 3350: <1% bound to plasma proteins.
Vd: 2.5-4.0 L/kg (indicates extensive tissue distribution; large Vd suggests accumulation in peripheral tissues).
PEG 3350: 0.58 L/kg (confined to extracellular fluid; minimal tissue penetration).
Oral: 65-80% (first-pass effect); IM: 90-100%; IV: 100%.
Oral: <0.06% for PEG 3350 (systemic absorption negligible). Electrolytes fully absorbed.
GFR 30-50 m L/min: reduce dose by 25%; GFR 15-29 m L/min: reduce dose by 50%; GFR <15 m L/min: avoid use.
Contraindicated in patients with GFR < 30 m L/min/1.73 m² due to risk of electrolyte abnormalities and fluid overload. For GFR 30-60: use with caution, monitor electrolytes and volume status; consider split-dose regimen.
Child-Pugh A: no adjustment; Child-Pugh B: reduce dose by 50%; Child-Pugh C: contraindicated.
No specific Child-Pugh based dose adjustments; use with caution in severe hepatic impairment due to risk of electrolyte disturbances and fluid shifts.
0.5-1 mg/kg IM or IV every 4-6 hours; maximum 4 mg/kg/day.
For colonoscopy: 4 L if ≥ 12 years old; for constipation: 0.5-1.5 g/kg/day (max 17 g/day) in children ≥ 6 months. Safety and efficacy not established for colonoscopy in children < 12 years; alternative polyethylene glycol products available.
Initiate at 50% of adult dose; titrate cautiously due to increased sensitivity and risk of adverse effects.
Use with caution due to increased risk of electrolyte imbalance, aspiration, and fluid overload. Consider split-dose regimen, monitor renal function and electrolytes. Lower starting dose for constipation: 8.5 g daily.
There is no FDA black box warning for ALPHACAINE.
No FDA black box warning.
Risk of systemic toxicity if injected intravascularly,Use with caution in patients with hepatic impairment,Use with caution in patients with cardiovascular disease,May cause methemoglobinemia in rare cases,Avoid use in patients with known hypersensitivity to amide-type anesthetics
Risk of fluid and electrolyte abnormalities,Serious arrhythmias in patients with pre-existing electrolyte disturbances,Seizures,Renal impairment,Aspiration risk in patients with impaired gag reflex,Colonic mucosal ulcerations
Hypersensitivity to ALPHACAINE or any component of the formulation,Severe hepatic impairment,Severe uncontrolled hypotension,Injection into infected or inflamed areas,History of malignant hyperthermia (relative contraindication)
Gastrointestinal obstruction,Gastric retention,Bowel perforation,Toxic colitis,Toxic megacolon,Ileus,Known hypersensitivity to any component
No clinically significant food interactions. Grapefruit juice does not affect clearance. Avoid excessive alcohol intake as it may increase risk of sedation and dizziness.
Avoid solid food during bowel preparation. Clear liquids only: water, clear broth, apple juice, white grape juice, black coffee or tea (no milk), clear sports drinks, gelatin without fruit. No red or purple colored liquids. Avoid alcohol.
FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and third trimesters: Potential for fetal growth restriction, preterm labor, and neurobehavioral alterations. Avoid use unless benefit outweighs risk.
Insufficient human data; animal studies not conducted. Use during pregnancy only if clearly needed. No known teratogenicity from limited reports.
Excreted in human milk; M/P ratio estimated at 0.95. Peak milk concentration occurs 1-2 hours after maternal dose. Limited data suggest low risk to term infants, but caution in preterm or ill infants. American Academy of Pediatrics recommends avoiding breastfeeding within 4 hours of maternal dose.
Excretion into breast milk unknown; polyethylene glycol is minimally absorbed systemically. Considered likely compatible with breastfeeding due to low absorption.
Increased volume of distribution and enhanced hepatic clearance (CYP3A4 induction) in pregnancy require 30-50% dose escalation. Monitor trough levels to achieve therapeutic range (5-15 mg/L). Postpartum dose should be reduced to pre-pregnancy levels within 72 hours.
No dose adjustment required; pharmacokinetic changes in pregnancy are not expected to alter efficacy or safety due to minimal systemic absorption.
ALPHACAINE (liposomal bupivacaine) provides extended analgesia up to 72 hours. Do not use with bupivacaine HCl or other local anesthetics as it may disrupt liposomal formulation. Avoid bolus injection; administer by slow infiltration only. Use with caution in hepatic impairment due to decreased clearance. Maximum dose: 266 mg (20 m L of 1.3% solution) in adults.
Administer in divided doses to improve tolerance. Ensure adequate hydration to prevent electrolyte imbalance. Contraindicated in ileus, gastrointestinal obstruction, perforation, gastric retention, or toxic colitis. Use with caution in patients with impaired gag reflex to reduce aspiration risk. Monitor renal function and electrolytes in elderly or debilitated patients.
You will receive a long-acting local anesthetic that provides pain relief for up to 3 days after surgery.,Do not apply heat or ice packs directly over the injection site for 24 hours.,Report any signs of infection such as redness, swelling, or warmth at the injection site.,Avoid driving or operating machinery for 24 hours if you feel dizzy or drowsy.,Take over-the-counter pain relievers as directed if breakthrough pain occurs.
Take this medication exactly as prescribed for bowel preparation before colonoscopy.,Mix the powder with clear liquids as directed; do not consume any solid food during preparation.,Drink additional clear fluids throughout the preparation to stay hydrated.,Expect frequent, watery bowel movements; stay near a toilet.,If you experience severe abdominal pain, vomiting, or inability to pass stool, contact your doctor immediately.
No interactions on record
No interactions on record
Explore head-to-head clinical comparisons of other medications in the same therapeutic classes.
Common clinical questions about ALPHACAINE vs POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES, answered by our medical review team.
ALPHACAINE is a Local Anesthetic that works by ALPHACAINE is a local anesthetic that binds to the intracellular portion of voltage-gated sodium channels, blocking sodium influx and preventing depolarization and conduction of nerve impulses.. POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES is a Bowel Evacuant that works by Polyethylene glycol 3350 is an osmotic laxative that acts by retaining water in the stool, increasing stool volume, and stimulating colonic peristalsis. Electrolytes (sodium sulfate, potassium sulfate, magnesium sulfate) are included to maintain fluid and electrolyte balance and prevent shifts.. They differ in pharmacokinetic profiles, FDA-approved indications, and side effect profiles.
Potency comparisons between ALPHACAINE and POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES depend on the specific clinical indication. These are agents from distinct pharmacological classes and are not directly interchangeable by dose. A physician or clinical pharmacist should guide any therapeutic switching decisions.
The standard adult dose of ALPHACAINE is: 10-20 mg IM or IV every 4-6 hours as needed; maximum 80 mg/day.. The standard adult dose of POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES is: 4 liters of PEG-3350 and electrolytes solution orally as a single dose for colonoscopy preparation; alternative split-dose regimen: 2 liters evening before and 2 liters morning of procedure. For constipation: 17 g (1 heaping tablespoon) dissolved in 8 oz water once daily, up to 3 days.. Dosing should always be individualized based on indication, renal and hepatic function, age, and other patient factors.
No direct drug-drug interaction has been formally documented between ALPHACAINE and POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES in current clinical databases. However, individual patient risk factors including other medications, organ function, and comorbidities should always be evaluated by a qualified healthcare provider.
The maternal-fetal safety profiles differ. ALPHACAINE is classified as Category C. FDA Category C. First trimester: Increased risk of spontaneous abortion and congenital anomalies (neural tube defects, cardiac malformations) based on animal studies. Second and th. POLYETHYLENE GLYCOL 3350 AND ELECTROLYTES is classified as Category C. Insufficient human data; animal studies not conducted. Use during pregnancy only if clearly needed. No known teratogenicity from limited reports.. Always consult a maternal-fetal medicine specialist before taking either drug during pregnancy or lactation.